文献速递慢性肾脏病

预测因素、差异与机构间变异:美国退伍军人慢性肾脏病患者中SGLT2抑制剂处方情况

Predictors, Disparities, and Facility-Level Variation: SGLT2 Inhibitor Prescription Among US Veterans With CKD.
PubMed 文献 · Am J Kidney Dis · 2023-01-23

该回顾性队列研究纳入174,443例合并2型糖尿病、慢性肾脏病和动脉粥样硬化性心血管疾病的美国退伍军人,其中20,024例(11.5%)被处方SGLT2抑制剂。黑人患者较白人患者处方比值更低(OR 0.87),女性较男性更低(OR 0.59),且机构间存在未解释的58%处方变异(MRR 1.58)。

要点

  • 在可能符合条件的退伍军人中,SGLT2抑制剂处方率仅11.5%。
  • 黑人患者较白人患者处方比值更低(OR 0.87 [95% CI 0.83-0.91])。
  • 女性较男性处方比值更低(OR 0.59 [95% CI 0.52-0.67])。

核心结论

  • 在可能符合条件的患者中SGLT2抑制剂处方率低,存在性别和种族差异以及退伍军人事务部机构间差异,需要研究和解决这些差异的原因以改善公平采用。

研究设计与样本

  • 回顾性队列研究,纳入2020年1月1日至12月31日期间有初级保健就诊的合并2型糖尿病、慢性肾脏病和动脉粥样硬化性心血管疾病的美国退伍军人全国样本,共174,443例。

主要发现

  • 174,443例患者中20,024例(11.5%)被处方SGLT2抑制剂。
  • 黑人患者较白人患者SGLT2抑制剂处方比值更低(OR 0.87 [95% CI 0.83-0.91])。
  • 女性较男性SGLT2抑制剂处方比值更低(OR 0.59 [95% CI 0.52-0.67])。
  • 总队列调整后MRR为1.58(95% CI 1.48-1.67),表明退伍军人事务部机构间存在未解释的58%治疗变异。
  • 黑人患者MRR为1.55(95% CI 1.41-1.68),白人患者MRR为1.57(95% CI 1.47-1.66),女性MRR为1.40(95% CI 1.28-1.51),男性MRR为1.57(95% CI 1.48-1.67)。

关键数值与推荐

  • SGLT2抑制剂被推荐用于合并慢性肾脏病或动脉粥样硬化性心血管疾病的2型糖尿病患者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 未评估白蛋白尿。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Sodium/glucose cotransporter 2 (SGLT2) inhibitors are recommended for type 2 diabetes mellitus (T2DM) in patients with chronic kidney disease (CKD) or atherosclerotic cardiovascular disease (ASCVD). We evaluated factors associated with SGLT2 inhibitor prescription, disparities by race and sex, and facility-level variation in prescription patterns. STUDY DESIGN: Retrospective cohort. SETTING & PARTICIPANTS: A national sample of US veterans with comorbid T2DM, CKD, and ASCVD with a primary care visit between January 1 and December 31, 2020. EXPOSURE: Race, sex, and individual Veterans Affairs (VA) location. OUTCOME: SGLT2 inhibitor prescription. ANALYTICAL APPROACH: Multivariable logistic regression assessed associations of race and sex with SGLT2 inhibitor prescription. Facility-level variation in SGLT2i prescription was quantified by median rate ratios (MRR), which express the likelihood that 2 randomly selected facilities differ in their use of SGLT2 inhibitor among similar patients. RESULTS: Of 174,443 patients with CKD, T2DM, and ASCVD, 20,024 (11.5%) were prescribed an SGLT2 inhibitor. Lower odds of SGLT2 inhibitor prescription were seen in Black or African American patients compared with White patients (OR, 0.87 [95% CI, 0.83-0.91]) and among women compared with men (OR, 0.59 [95% CI 0.52-0.67]). The adjusted MRR for SGLT2 inhibitor prescription was 1.58 (95% CI 1.48-1.67) in the total cohort, indicating an unexplained 58% variation in treatment between VA facilities, independent of patient and facility characteristics. Facility-level variation was evaluated among Black or African American patients (MRR, 1.55 [95% CI 1.41-1.68]), White patients (MRR, 1.57 [95% CI 1.47-1.66]), women (MRR, 1.40 [95% CI 1.28-1.51]), and men (MRR, 1.57 [95% CI 1.48-1.67]). LIMITATIONS: Albuminuria was not assessed. CONCLUSIONS: Prescription for SGLT2 inhibitors was low among likely eligible patients, with evident disparities by sex and race and between individual VA facilities. Efforts are needed to study and address the reasons for these disparities to improve equitable adoption of these important medications.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Gregg LP, Ramsey DJ, Akeroyd JM, et al. Predictors, Disparities, and Facility-Level Variation: SGLT2 Inhibitor Prescription Among US Veterans With CKD. Am J Kidney Dis. 2023. PMID: 36702340. doi:10.1053/j.ajkd.2022.11.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。